Thursday, July 14, 2022
Alliance Pharma (Alliance), a U.S. leader in small and large molecule bioanalytical services in the pharmaceutical and biopharmaceutical industry, today closed on the purchase of Drug Development Solutions (DDS), a U.K.-based bioanalytical and material science testing contract research organization (CRO), from LGC. Ampersand Capital Partners, a global healthcare private equity firm, and KKR & Co. Inc. (KKR) (NYSE:KKR), a leading global investment firm, are equal shareholders in the combined company. This transaction expands bioanalytical, analytical material testing and laboratory capabilities internationally for the biopharma and pharma industry, including areas of cell and gene therapy, next-generation biologics, material sciences and protein characterization
“Together, Alliance and DDS will partner with customers on a global basis to provide advanced bioanalytical and analytical material services for both large and small molecules, particularly supporting many emerging bioanalytical and analytical science areas the industry needs right now,” said Alliance Chairman of the Board and a Partner at Ampersand Capital Partners Dave Patteson. “Alongside Alliance’s bioanalytical expertise, DDS adds an unrivalled breadth and depth of expertise in bioanalysis and analytical and materials science as well as two state-of-the-art analytical labs in Cambridge (Fordham), U.K., and Sandwich, Kent, U.K. Their Cambridge facility is one of the largest bioanalytical centers in the world with about 270 employees.”
This acquisition positions Alliance to become an international bioanalytical service provider for all therapeutic modalities.